Laboratorios Farmaceuticos ROVI Osake

Laboratorios Farmaceuticos ROVI PEG

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Laboratorios Farmaceuticos ROVI (ROVI.MC) 30.7.2026 päivämäärällä on 7,49.

PEG

7,49

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Laboratorios Farmaceuticos ROVI on 2026 7,49 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Laboratorios Farmaceuticos ROVI oli 2025 0,00 . Se laskee % korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Laboratorios Farmaceuticos ROVI Osakeanalyysi

Mitä Laboratorios Farmaceuticos ROVI tekee? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Laboratorios Farmaceuticos ROVI osakkeesta

Yhtiön Laboratorios Farmaceuticos ROVI PEG-suhde (Hinta-tuotto-kasvu-suhde) on 7,49 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — Laboratorios Farmaceuticos ROVI

Kaikki tunnusluvut — Laboratorios Farmaceuticos ROVI